Holen Sie sich die Stockscreener-App
0.8369
2.81%
-0.0242
Handel nachbörslich:
.84
0.0031
+0.37%
Schlusskurs vom Vortag:
$0.8611
Offen:
$0.85
24-Stunden-Volumen:
93,038
Relative Volume:
0.04
Marktkapitalisierung:
$10.03M
Einnahmen:
$285.80K
Nettoeinkommen (Verlust:
$-12.60M
KGV:
-0.4239
EPS:
-1.9743
Netto-Cashflow:
$-13.44M
1W Leistung:
-7.76%
1M Leistung:
+22.53%
6M Leistung:
-41.06%
1J Leistung:
-52.18%
1-Tages-Spanne:
$0.8067
$0.8608
1-Wochen-Bereich:
$0.8067
$0.9986
52-Wochen-Spanne:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.8369 | 10.32M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study - MyChesCo
Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan
Two life sciences companies with Doylestown connections raise $119M - MSN
Aprea (APRE): Buy, Sell, or Hold? | Q4 2025: EPS Beats ForecastsEV/EBITDA - Xã Vĩnh Công
Aprea Therapeutics (NASDAQ: APRE) registers 74.35M shares for resale by investors - Stock Titan
Aprea Therapeutics abstract accepted at ASCO meeting in May - Investing.com
Aprea Therapeutics abstract accepted at ASCO meeting in May By Investing.com - Investing.com Canada
Aprea Therapeutics Announces Acceptance of Abstract for Phase 1 Study of WEE1 Inhibitor APR-1051 at ASCO 2026 - Quiver Quantitative
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Weekly Voice
Early human data on Aprea cancer drug lands ASCO 2026 poster slot - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) seeks board authority for 1‑for‑3–1‑for‑8 reverse split - Stock Titan
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea (APRE) Stock: Why It Matters Now (Eye on Rally) 2026-04-18Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Lào Cai
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
10 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
APRE Forecast, Price Target & Analyst Ratings | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
APRE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
3 Reasons to Avoid PTLO and 1 Stock to Buy Instead - Barchart.com
Analyst Calls: Is Aprea Therapeutics Inc stock a buy or sell2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Merger Talk: Is Aprea Therapeutics Inc affected by consumer sentimentWeekly Risk Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
3 Reasons HUBG is Risky and 1 Stock to Buy Instead - Barchart.com
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart
Aug Macro: How does Aprea Therapeutics Inc perform in inflationary periodsCPI Data & Precise Buy Zone Tips - baoquankhu1.vn
What is the biggest uncertainty for Aprea (APRE) Stock | Price at $0.86, Up 17.17%AI Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
APRE Breaks Key Resistance—But Bears Still Lurk Below - Bitget
Janus and Tecnoglass Shares Are Soaring, What You Need To Know - Barchart.com
Why Trex (TREX) Stock Is Up Today - Barchart.com
Stryker (SYK): Buy, Sell, or Hold Post Q4 Earnings? - Barchart.com
Simply Good Foods (SMPL) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Squadron reports 1.27M warrant stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Reports Partial Response in APR-1051 Cancer Trial - MyChesCo
Why Apple (AAPL) Shares Are Falling Today - Barchart
Former Aprea CEO Christian Schade joins Frazier after Halda sale - Stock Titan
Here's What to Expect From 3M Company's Next Earnings Report - Barchart
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
APRE Stock Analysis: Aprea Therapeutics Inc. Common Stock Up 1.65 Pct at 0.72 USD - Cổng thông tin điện tử tỉnh Lào Cai
Stocks in play: CGI Inc. - Barchart.com
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):